Literature DB >> 23286946

Changes in B cell immunophenotype in common variable immunodeficiency: cause or effect - is bronchiectasis indicative of undiagnosed immunodeficiency?

P Bright1, S Grigoriadou, P Kamperidis, M Buckland, A Hickey, H J Longhurst.   

Abstract

Common variable immunodeficiency (CVID) is the most common severe primary immunodeficiency, but the pathology of this condition is poorly understood. CVID involves a defect in the production of immunoglobulin from B cells, with a subsequent predisposition to infections. Approximately 10-20% of cases are inherited, but even in families with a genetic defect the penetrance is far from complete. A classification system for CVID has been suggested (EUROclass) based on B cell immunophenotyping, but it has not been shown that altered B cell immunophenotype is not a consequence of the complications and treatment of CVID. This study compares the EUROclass B cell immunophenotype of CVID patients (n = 30) with suitable disease controls with bronchiectasis (n = 11), granulomatous disease (Crohn's disease) (n = 9) and neurological patients on immunoglobulin treatment (n = 6). The results of this study correlate with previous literature, that alterations in B cell immunophenotype are associated strongly with CVID. Interestingly, three of the 11 bronchiectasis patients without known immunodeficiency had an altered B cell immunophenotype, suggesting the possibility of undiagnosed immunodeficiency, or that bronchiectasis may cause a secondary alteration in B cell immunophenotype. This study showed a significant difference in B cell immunophenotype between CVID patients compared to disease control groups of granulomatous disease and immunoglobulin treatment. This suggests that granulomatous disease (in Crohn's disease) and immunoglobulin treatment (for chronic neurological conditions) are not causal of an altered B cell immunophenotype in these control populations.
© 2012 Crown copyright.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23286946      PMCID: PMC3573290          DOI: 10.1111/cei.12010

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

Review 1.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

2.  Deficient IL-12 and dendritic cell function in common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles; Lin Radigan
Journal:  Clin Immunol       Date:  2005-05       Impact factor: 3.969

3.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

4.  Failure in antigen responses by T cells from patients with common variable immunodeficiency (CVID).

Authors:  A J Stagg; M Funauchi; S C Knight; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

Review 5.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  Measurement of peripheral B cell subpopulations in common variable immunodeficiency (CVID) using a whole blood method.

Authors:  B L Ferry; J Jones; E A Bateman; N Woodham; K Warnatz; M Schlesier; S A Misbah; H H Peter; H M Chapel
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

7.  Primary defect in CD8+ lymphocytes in the antibody deficiency disease (common variable immunodeficiency): abnormalities in intracellular production of interferon-gamma (IFN-gamma) in CD28+ ('cytotoxic') and CD28- ('suppressor') CD8+ subsets.

Authors:  M E North; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

8.  Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease.

Authors:  Klaus Warnatz; Axel Denz; Ruth Dräger; Moritz Braun; Christoph Groth; Guido Wolff-Vorbeck; Hermann Eibel; Michael Schlesier; Hans Hartmut Peter
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

9.  Common variable immunodeficiency is associated with defective functions of dendritic cells.

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Lionel Galicier; Yves Lepelletier; David Webster; Yves Lévy; Martha M Eibl; Eric Oksenhendler; Olivier Hermine; Srini V Kaveri
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

10.  Humoral immunity and bronchiectasis.

Authors:  A Stead; J G Douglas; C J Broadfoot; E R Kaminski; R Herriot
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

View more
  4 in total

1.  Lymphocyte Subgroups and KREC Numbers in Common Variable Immunodeficiency: A Single Center Study.

Authors:  Ismail Yaz; Begum Ozbek; Yuk Yin Ng; Pinar Gur Cetinkaya; Sevil Oskay Halacli; Cagman Tan; Merve Kasikci; Can Kosukcu; Ilhan Tezcan; Deniz Cagdas
Journal:  J Clin Immunol       Date:  2020-02-14       Impact factor: 8.317

2.  Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study.

Authors:  Mehdi Mirsaeidi; Roberto F Machado; Joe G N Garcia; Dean E Schraufnagel
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

3.  Variable immunodeficiency score upfront analytical link (VISUAL), a proposal for combined prognostic score at diagnosis of common variable immunodeficiency.

Authors:  Kissy Guevara-Hoyer; Adolfo Jiménez-Huete; Julia Vasconcelos; Esmeralda Neves; Silvia Sánchez-Ramón
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

4.  Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement.

Authors:  Sai S Duraisingham; Matthew Buckland; John Dempster; Lorena Lorenzo; Sofia Grigoriadou; Hilary J Longhurst
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.